Aitiologic raises €6.4M seed for AI-powered liquid biopsy in pregnancy risk

Aitiologic said it closed an oversubscribed €6.4 million (about $7.4 million) seed round co-led by Heal Capital and Ananda Impact Ventures. Funds go to large-scale validation and regulated development of Aitios®, a multi-modal cell-free DNA liquid-biopsy platform that combines genomic, epigenomic, and fragmentomic markers with AI-based interpretation — starting with first-trimester preeclampsia risk stratification from the same blood draw used for NIPT.

HEALTH desk priority — same-day company primary funding a medical-AI liquid-biopsy platform aimed at earlier preeclampsia risk detection from an existing prenatal blood draw.

The round was co-led by Heal Capital and Ananda Impact Ventures, the company said. Early backers PUSH VC and LANA Ventures continued. Dr. Gordon Sanghera CBE FRS — co-founder and former CEO of Oxford Nanopore Technologies — participated as an investor and joins the advisory board. File the €6.4 million / about-$7.4 million figure, the two co-leads, those continuing backers, and the Sanghera investor-plus-advisor line as Aitiologic’s. This desk is not inventing a valuation, an ownership percentage, or a check size. None was printed.

Proceeds, still company: support large-scale validation and regulated product development of Aitios®, Aitiologic’s multi-modal cell-free DNA (cfDNA) platform. Multi-modal here means the test reads more than one kind of DNA signal from the same blood sample. File that spend plan and that platform name as Aitiologic’s. This desk did not sit in a board meeting.

How Aitios® works, as the company tells it: the platform combines genomic, epigenomic, and fragmentomic cfDNA signals with AI-based / AI-powered interpretation to infer tissue of origin and tissue-specific biological changes from a routine blood draw. Genomic means the DNA sequence. Epigenomic means chemical marks on DNA that turn genes on or off. Fragmentomic means the size and breakage pattern of those short DNA pieces. Tissue of origin means which organ or tissue a DNA fragment came from. File that product picture as Aitiologic’s. This desk did not run a blood test.

Lead program, still company: first-trimester preeclampsia risk stratification using the same blood sample already drawn for non-invasive prenatal testing (NIPT) — no extra draw claimed. First-trimester means the first three months of pregnancy. Risk stratification means sorting who is more likely to need closer watch or prevention. File that same-draw job as Aitiologic’s stated aim. This desk is not treating it as a proven clinical result.

Study context, company-attributed — not independently verified here: Aitiologic cites ongoing large-scale validation in more than 1,000 pregnancies, including work with the Fetal Medicine Foundation, and prior feasibility work with Professor Kypros Nicolaides and the Fetal Medicine Research Institute. File that more-than-1,000-pregnancies line and those names as Aitiologic’s. This desk did not review the study file or rerun the feasibility work.

Appointment, company: Dr. Rebecca Ertl, an obstetrician-gynecologist and founder of a prenatal diagnostics center, was named Chief Medical Officer. File the name and title as Aitiologic’s. Her quotes are color only and stay in Sources.

Technology foundation, still company: Aitios® builds on patented tissue-specific liquid biopsy technology co-invented by CEO Dr. Andreas E. Posch at Siemens Healthineers and exclusively licensed to Aitiologic. File that license line as Aitiologic’s. This desk did not read the patent file as a second primary.

The company states Aitios® is under development and is not yet approved or available for clinical use. File that as Aitiologic’s. This desk is not inventing FDA or EMA clearance, clinical efficacy, or a U.S. commercial launch.

Plain English for the rest of the card: liquid biopsy = lab tests on blood that look for DNA or other signals from tissues without surgery. cfDNA = short DNA fragments floating in blood. preeclampsia = a dangerous high-blood-pressure disorder in pregnancy. NIPT = a common prenatal blood test for chromosomal conditions. seed = early funding round. tissue of origin = which organ or tissue a DNA fragment came from.

PRIMARY here: Aitiologic’s 15 Sep 2026 company announcement — Tier A PRIMARY company source, the original record — read here via the LISAvienna reprint and the same-day Health Technology Net wire reprint of that originating text. The company site is product-home context, not a second originating newsroom. The significantly oversubscribed €6.4 million / about-$7.4 million seed, the Heal Capital and Ananda Impact Ventures co-leads, PUSH VC / LANA Ventures, Sanghera as investor and advisor, Aitios® multi-modal cfDNA plus AI-based interpretation, the first-trimester preeclampsia / same-NIPT-draw lead program, the more-than-1,000-pregnancies validation and Nicolaides / Fetal Medicine Research Institute / Fetal Medicine Foundation feasibility lines, the Ertl CMO appointment, the Posch / Siemens Healthineers licensed foundation, and the not-yet-approved clinical-use caveat are company-attributed. Study size and feasibility stay company-attributed — not independently verified here. NOT claimed: a valuation, FDA or EMA approval, independently verified clinical efficacy, a U.S. commercial launch, that Aitios® is available for clinical use, that this desk reviewed a study file or saw a term sheet, a stock tip, or investment advice. Distinct from the already-filed openai-foundation-public-data-health, unc-openai-foundation-40m-cancer-vaccines, insilico-longevity-vaccines, openevidence-penn-medicine, microstructure-imaging-micsi-pet-fda, sonus-medtronic-maternal-ultrasound-ai, powerful-medical-queen-of-hearts-fda-de-novo, kairon-health-5m, evvy-40m-series-b, hello-patient-acquires-converse, medallion-acquires-andros, knowtex-frontier-ai-lab, azmed-azchest-fda-6th, curvebeam-ai-fda-ct-bmd-510k, and nvidia-chop-cardiac-monai.